We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer (DISCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04766190
Recruitment Status : Recruiting
First Posted : February 23, 2021
Last Update Posted : June 1, 2022
Sponsor:
Information provided by (Responsible Party):
Lauren Hamel, Barbara Ann Karmanos Cancer Institute

Brief Summary:
The DISCO App is designed to improve, during the interaction, patient active participation and patient-initiated oncologist treatment cost discussions, and, in the short term, patient's treatment cost knowledge, self-efficacy for managing both cost and physician interactions, referrals, perceived financial toxicity (i.e., distress and material hardship); in turn, these will affect longer-term outcomes of financial toxicity and adherence.

Condition or disease Intervention/treatment Phase
Financial Toxicity Cancer Question Prompt List Breast Cancer Prostate Cancer Behavioral: Group 2: The DISCO App Behavioral: Group 1: Usual Care Behavioral: Group 3: The DISCO App + Booster Not Applicable

Detailed Description:
This work is based on the core scientific premise - that increasing patient active participation and the frequency and quality of treatment cost discussions will decrease the short- and longer-term burdens of financial toxicity through their influence on self-efficacy for managing treatment cost. The focus is on patient self-efficacy for managing treatment cost because it is expected that improved treatment cost education and patient-oncologist treatment cost discussions prompted by the DISCO App will directly improve the self-efficacy needed for patients to proactively manage treatment costs, thus reducing the material and psychological burden of financial toxicity. The DISCO App is not designed to increase patients' ability to pay or reduce the cost of treatment, but it may benefit patients by increasing: their knowledge of treatment costs, their self-efficacy for managing cost, and the likelihood they receive financial and psychological assistance and support. This research is significant because, if successful, reducing the material and psychological burden of financial toxicity will improve the quality of care and work toward achieving health equity. The DISCO App has already been tested for its feasibility and acceptability. The DISCO App will now be tested for its effectiveness in a diverse population of people with solid tumors treated with IV and oral chemotherapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The research tests the effectiveness of an application-based ("app") communication intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions during clinical interactions, and associated measures.
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
Actual Study Start Date : February 10, 2021
Estimated Primary Completion Date : August 31, 2025
Estimated Study Completion Date : August 31, 2025

Arm Intervention/treatment
Group 1: Usual Care

The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.

The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study.

Behavioral: Group 1: Usual Care
Patients randomized to this arm will receive usual care.

Group 2: The DISCO App

The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.

The patient will be shown an iPad with an "app" while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study.

Behavioral: Group 2: The DISCO App
Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.

Group 3: The DISCO App + Booster

The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.

The patient will be shown an iPad with an "app" while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app.

Behavioral: Group 3: The DISCO App + Booster
Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.




Primary Outcome Measures :
  1. Self-efficacy in patient-physician interactions. An example item from the PEPPI scale: How confident are you in your ability to know what questions to ask your doctor? Data will be aggregated using means and standard deviations. [ Time Frame: Immediately after the video-recorded patient-physician interaction ]
    How efficacious patients feel about communicating with physicians. Scale title: Self-efficacy in patient-physician interactions. Minimum = 1; Maximum = 5; higher is a better outcome.

  2. Self-efficacy in managing treatment costs An example item from adapted scale: I am confident I can pay for the direct costs of my treatment. Data will be aggregated using means and standard deviations. [ Time Frame: Immediately after video-recorded patient-physician interaction ]
    How efficacious patients feel about managing their treatment costs. Scale title: Self-efficacy in managing treatment costs. Minimum = 1; Maximum = 5; higher is a better outcome.

  3. Knowledge of types of treatment cost An example item from the original measure: Cancer treatment may cost me in the following ways? Data will be aggregated using frequency counts. [ Time Frame: Immediately after video-recorded patient-physician interaction ]
    If patients know the types of cost associated with cancer treatment

  4. Perceived financial toxicity; Scale title: Adapted Comprehensive score for financial toxicity (COST) measure. [ Time Frame: Immediately after video-recorded patient-physician interaction ]
    Anticipated financial harm due to treatment cost. Scale title: Adapted Comprehensive score for financial toxicity (COST) measure. Minimum = 0; Maximum = 4; lower is a better outcome.

  5. Perceived presence of treatment cost discussion [ Time Frame: Immediately after video-recorded patient-physician interaction ]
    Patient perception that treatment cost discussed with the physician

  6. Patient self-report of level of satisfaction with any treatment cost discussions with physician assessed via an original scale: satisfaction with any treatment cost discussed with the physician that occurred. [ Time Frame: Immediately after video-recorded patient-physician interaction ]
    Scale title: Satisfaction with any treatment cost discussed with the physician that occurred. Minimum = 1; Maximum = 5; higher is a better outcome.

  7. The observed frequency of a cost discussion assessed via an original coding system. Frequency is assessed as the number of distinct cost discussions that occur in each recorded interaction. Higher is a better outcome. [ Time Frame: During the video-recorded patient-physician interaction ]
    Observation of the frequency of a cost discussion. Minimum = 0; Maximum = undefined.

  8. Patient-Centered Communication scale. The observed quality of patient-physician communication assessed a validated coding system. Minimum = 1; Maximum =5; higher is a better outcome [ Time Frame: During the video-recorded patient-physician interaction ]
    Observation of the quality of patient-physician communication.

  9. Referral to social work/financial navigator [ Time Frame: Immediately after video-recorded patient-physician interaction ]
    If the patient was referred to a social worker or financial navigator. The number of patients who receive a referral to a social worker or a financial navigator.


Secondary Outcome Measures :
  1. Self-efficacy in patient-physician interactions. An example item from the PEPPI scale: How confident are you in your ability to know what questions to ask your doctor? Data will be aggregated using means and standard deviations. [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
    How efficacious patients feel about communicating with physicians. Scale title: Self-efficacy in patient-physician interactions. Minimum = 1; Maximum = 5; higher is a better outcome.

  2. Self-efficacy in managing treatment costs [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]

    How efficacious patients feel about managing their treatment costs. Scale title: Self-efficacy in managing treatment costs. Minimum = 1; Maximum = 5; higher is a better outcome.

    An example item from the adapted scale: I am confident I can pay for the direct costs of my treatment.

    Data will be aggregated using means and standard deviations.


  3. Financial toxicity [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
    The experience of financial harm due to treatment cost. Rate of patients who indicate they are experiencing financial burden due to cancer treatment costs.

  4. Follow up with social work/financial navigator [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]

    If the patient followed up with social work/financial navigator if referred.

    Data will be aggregated using frequency counts.


  5. Treatment adherence An example item from the Medical Outcomes Study General Adherence measure: I had a hard time doing what the doctor suggested I do for treating my cancer. [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
    If the patient adhered to the recommended treatment

  6. Treatment-cost related adherence [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
    If the patient was unable to adhere to treatment due to cost

  7. Clinical appointment adherence. The rate of appointments a patient is scheduled for and attends. [ Time Frame: 1, 3, 6, and 12 months after video-recorded patient-physician interaction ]
    If the patient adhered to clinical appointments


Other Outcome Measures:
  1. Assessment of the intervention. [ Time Frame: Immediately after video-recorded patient-physician interaction ]

    Patient perceptions of the intervention's usefulness using an original scale.

    An example item from the original measure: The DISCO App helped me ask my doctor my cost questions. Minimum = 1; Maximum = 5; higher is a better outcome.


  2. Assessment of the intervention booster An example item from the original measure: The reminder email or text message was helpful with my cost questions and concerns. [ Time Frame: 1 month after the video-recorded patient-physician interaction ]
    Patient perceptions of the intervention booster's usefulness

  3. Intervention presence in video-recorded patient-physician interaction [ Time Frame: During the video-recorded patient-physician interaction ]
    If the interaction is visible in the video-recorded patient-physician interaction



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Oncologists are eligible if they treat patients with breast, prostate, lung, or colorectal cancers at Karmanos Cancer Institute. Data from oncologists will include their self-report data and video-recorded treatment discussions with participating patients.
  • Patients: Must be able to read and write in English; have an email account; and are newly diagnosed with breast, prostate, lung or colorectal cancer (stage I-IV) for which systemic therapy is a likely recommended treatment. Data from patients will include their self-report data, video-recorded treatment discussions with participating oncologists, and medical record data

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04766190


Contacts
Layout table for location contacts
Contact: Lauren Hamel, PhD 313-576-9672 hamell@karmanos.org

Locations
Layout table for location information
United States, Michigan
Barbara Ann Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Lauren Hamel, PhD    313-576-9672    hamell@karmanos.org   
Sub-Investigator: Susan Eggly, PhD         
Sub-Investigator: Seongho Kim, PhD         
Sub-Investigator: Elisabeth Heath, M.D.         
Sponsors and Collaborators
Lauren Hamel
Investigators
Layout table for investigator information
Principal Investigator: Lauren Hamel, PhD Barbara Ann Karmanos Cancer Insitute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lauren Hamel, Principal Investigator, Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier: NCT04766190    
Other Study ID Numbers: 2020-117
RSG-20-026-01 - CPHPS ( Other Grant/Funding Number: American Cancer Society )
First Posted: February 23, 2021    Key Record Dates
Last Update Posted: June 1, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lauren Hamel, Barbara Ann Karmanos Cancer Institute:
Financial Toxicity
Cancer
Treatment cost
Patient-provider communication
Additional relevant MeSH terms:
Layout table for MeSH terms
Financial Stress
Stress, Psychological
Behavioral Symptoms